About this trial
This study aims to evaluate the effect of continuous erector spinae plane block (CESPB) using ropivacaine on postoperative pain in patients undergoing elective mastectomy. In addition to pain control, this study investigates the impact of CESPB on systemic inflammatory response as measured by nuclear factor kappa B (NF-κB) levels, opioid consumption, and quality of recovery. Patients will be randomly assigned to receive CESPB or standard analgesia without block. Outcomes will be assessed within the first 24 hours after surgery. The findings are expected to provide evidence on the clinical and biological benefits of CESPB as part of multimodal analgesia in breast surgery.
Eligibility criteria
Qualifiers
Female patients aged 18 to 65 years
Diagnosed with breast cancer
Scheduled for elective mastectomy under general anesthesia
American Society of Anesthesiologists (ASA) physical status I-III
Disqualifiers
Contraindications to regional anesthesia
Contraindications or allergy to ropivacaine or local anesthetics
Inability to use a visual analog scale (VAS) for pain assessment
Inability to understand or operate patient-controlled analgesia (PCA)
Trial design
Treatments tested in this trial
- Continuous Erector Spinae Plane Block
- Ropivacaine
Treatment groups
Sponsors and collaborators
Aldy Aldy
Lead sponsor
Udayana University
Sponsor institution